Ignite Creation Date:
2025-12-25 @ 2:32 AM
Ignite Modification Date:
2026-02-24 @ 2:30 PM
Study NCT ID:
NCT03081234
Status:
WITHDRAWN
Last Update Posted:
2018-03-15
First Post:
2017-03-01
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Breast Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Hormone receptor-positive | View |
| None | Estrogen and/or progesterone receptor-positive | View |
| None | HER2-negative | View |
| None | Intermediate risk early breast cancer | View |
| None | Adjuvant | View |
| None | Ribociclib | View |
| None | LEE011 | View |
| None | CDK4/6 inhibitor | View |
| None | Endocrine therapy | View |
| None | Phase III | View |
| None | breast carcinoma | View |
| None | breast cancer | View |